TRAW

#4783
Traws Pharma, Inc. - Common Stock
0.5 9 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.59
0.60
Intervallo Annuale
0.43
3.25
Variazione giornaliera
0.00%
Variazione Mensile
+25.53%
Variazione di 6 mesi
-63.35%
Variazione Annuale
-58.45%
Chiusura Precedente
0.5 9
Open
0.5 9
Minimo
0.5 9
Massimo
0.6 0
Volume
4
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Traws Pharma, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K

Traws Pharma, Inc. current report, Q2 FY2024

Full document

Business Context and Reporting Period

This Form 8-K, dated April 1, 2024, reports the completion of a business combination between Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Following the merger, the company changed its name to Traws Pharma, Inc. and its ticker symbol changed from "ONTX" to "TRAW" on April 3, 2024. The transaction was structured as a tax-free reorganization.

Key Financial Metrics and Capital Structure

  • Financing: Concurrent with the merger, the company raised approximately $14 million through a private placement (PIPE) with affiliates of Torrey Pines and OrbiMed.
  • Equity Issuance (Merger): The company issued 3,549,538 shares of Common Stock and 10,359.0916 shares of Series C Preferred Stock to Trawsfynydd stockholders.
  • Equity Issuance (PIPE): The company issued 496,935 shares of Common Stock and 1,578.2120 shares of Series C Preferred Stock to PIPE investors.
  • Outstanding Shares: Following the closing, there were 25,301,009 shares of Common Stock issued and outstanding.
  • Series C Preferred Stock: Each share is convertible into 10,000 shares of Common Stock. It is non-voting but has protective provisions regarding fundamental transactions.
  • Debt and Liquidity: The filing text does not provide specific values for total debt, cash on hand, or liquidity ratios.
  • Revenue and Profit: The filing text does not provide revenue, profit, or margin data.

Material Changes and Agreements

  • Merger Completion: Trawsfynydd merged into a subsidiary of the Company, becoming a wholly-owned subsidiary. The Company assumed all outstanding Trawsfynydd stock options (454,000 shares), exercisable only after stockholder approval of specific proposals.
  • Contingent Value Rights (CVRs): The company issued CVRs to Common Stock holders of record on April 15, 2024. Holders are entitled to:
    • 43.7% of Net Proceeds from the sale or license of Rigosertib or Narazaciclib.
    • 6.24% of Net Sales for Rigosertib or Narazaciclib.
  • Lock-up Agreements: Certain stockholders, directors, and officers are subject to a 180-day lock-up on the sale of shares received in the merger.
  • Stockholder Support: Support agreements were executed with Company and Trawsfynydd stockholders to vote in favor of the Conversion Proposal and Share Increase Proposal.

Management Changes, Guidance, and Risks

Leadership Changes

  • Resignations: Dr. Steven M. Fruchtman (CEO), Peter Atadja, Jerome Groopman, Viren Mehta, and Mark Guerin (COO) resigned from the Board. Dr. Fruchtman and Mark Guerin also resigned from their executive roles, though Dr. Fruchtman remains President and Chief Scientific Officer, Oncology, and Mr. Guerin remains CFO.
  • Appointments:
    • Werner Cautreels: Appointed CEO and Director. Base salary $600,000; granted 200,000 RSUs.
    • Iain Dukes: Appointed Executive Chairman and Director. Base salary $350,000; granted 67,500 RSUs.
    • Nikolay Savchuk: Appointed COO and Director. Base salary $350,000; granted 67,500 RSUs.
    • Others: C. David Pauza appointed Chief Scientific Officer, Virology; Robert Redfield appointed Chief Medical Officer.

Outlook and Risks

  • Stockholder Approval Required: The conversion of Series C Preferred Stock and a charter amendment to authorize sufficient shares for conversion require stockholder approval via a proxy statement.
  • Financial Statements: Pro forma financial information and financial statements of the acquired business are expected to be filed within 71 days.
  • Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements regarding the merger and future prospects.

Investor Verification Checklist

  • Verify the terms of the Contingent Value Rights (CVRs) regarding the specific definitions of "Net Proceeds" and "Net Sales" for Rigosertib and Narazaciclib.
  • Confirm the timeline for the stockholder meeting required to approve the conversion of Series C Preferred Stock.
  • Review the upcoming proxy statement (Schedule 14A) for details on the Share Increase Proposal and voting procedures.
  • Monitor the filing of pro forma financial information (due within 71 days) to assess the combined entity's financial position.
  • Check the lock-up expiration dates for insiders and PIPE investors to gauge potential near-term selling pressure.